Workflow
Mitapivat
icon
搜索文档
Agios Pharma: Study Fail May Affect Mitapivat TDT Approval - Expect More Volatility (AGIO)
Seeking Alpha· 2025-11-20 03:43
If you are interested in keeping up to date with stocks making moves within the biotech, pharma, and healthcare industries and understanding the key trends and catalysts driving valuations ahead of the market, why not subscribe to my weekly newsletter via my Investing Group, Haggerston BioHealth ?The stock of Agios Pharmaceuticals, Inc. ( AGIO ) has hit the skids in trading today - down 49% at the time of writing, trading at $23 per share, which translates to a market cap valuation of ~$1.4bn.Edmund Ingham ...
Agios Pharmaceuticals, Inc. (AGIO) Discusses Topline Results from RISE UP Phase 3 Trial of Mitapivat in Sickle Cell Disease - Slideshow (NASDAQ:AGIO) 2025-11-19
Seeking Alpha· 2025-11-19 23:24
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...